01 March 2002
Interferon alpha in chronic hepatitis B treatment in a child with diagnosed linear IgA bullous dermatosis (LABD)
Dariusz Marek Lebensztejn , Maciej Kaczmarski , Bożena OlkowskaCase Rep Clin Pract Rev 2002; 3(1):36-39 :: ID: 475114
Abstract
Background: Interferon alpha treatment is a first choice therapy in children with chronic hepatitis caused by HBV infection.
Case report: The aim of the study was to present the IFN alpha application in chronic hepatitis as a cause of HBV superinfection in a 9-year-old child with diagnosed linear IgA bullous dermatosis (LABD). During 20-week
IFN alpha therapy we did not observe side-effects of the treatment; we observed HBeAg/antiHBe seroconversion, normalization of AlAT activity, regression of HBV DNA polymerase activity in blood serum and improvement
of skin lesions.
Conclusions: The disease history analysis of the treated boy indicates that application of IFN alpha in chronic hepatitis caused by HBV superinfection is possible in treatment of individual cases of children with autoimmunity
disorders. The clear-sighted monitoring of liver function and autoimmunity parameters are recommended.
Keywords: chronic hepatitis, HBV infection, interferon alpha, LABD, children
479
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






